Literature DB >> 26581846

Cutoff value of thyroid uptake of (99m)Tc-pertechnetate to discriminate between Graves' disease and painless thyroiditis: a single center retrospective study.

Toyoyoshi Uchida1, Ruriko Suzuki, Takatoshi Kasai, Hiroyuki Onose, Koji Komiya, Hiromasa Goto, Kageumi Takeno, Shinya Ishii, Junko Sato, Akira Honda, Yui Kawano, Miwa Himuro, Emiko Yamada, Tetsu Yamada, Hirotaka Watada.   

Abstract

Thyroid uptake of (99m)Tc-pertechnetate is a useful way to determine the cause of thyrotoxicosis. In daily clinical practice, (99m)Tc-pertechnetate uptake is used to discriminate between Graves' disease and painless thyroiditis when clinical information is not enough to make the distinction. However, since the optimal cutoff value of (99m)Tc-pertechnetate uptake has not yet been elucidated, our aim was to determine this value. We recruited patients with thyrotoxicosis in whom (99m)Tc-pertechnetate uptake was measured in clinical settings between 2009 and 2013. Three experienced endocrinologists (who were blinded to the value of (99m)Tc-pertechnetate uptake and initial treatment) diagnosed the cause of thyrotoxicosis based on thyrotropin, free triiodothyronine, free thyroxine, and thyrotropin receptor antibody levels, and by ultrasound findings and using images of thyroid uptake of (99m)Tc-pertechnetate without the actual values. Ninety-four patients diagnosed as having Graves' disease or painless thyroiditis were finally included. According to the diagnosis, the optimal cutoff value of (99m)Tc-pertechnetate uptake was determined by receiver operating characteristics analysis. A cutoff value of 1.0% provided optimal sensitivity and specificity of 96.6% and 97.1%, respectively. Then, its validity was confirmed in 78 patients with confirmed Graves' disease or painless thyroiditis diagnosed at another institute. Applying this cutoff value to the patients with thyrotoxicosis revealed positive and negative predictive values for Graves' disease of 100% and 88.9%, respectively. In conclusion, a cutoff value for (99m)Tc-pertechnetate uptake of 1.0% was useful to discriminate between Graves' disease and painless thyroiditis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26581846     DOI: 10.1507/endocrj.EJ15-0441

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  6 in total

Review 1.  ANGPTL8 roles in proliferation, metabolic diseases, hypothyroidism, polycystic ovary syndrome, and signaling pathways.

Authors:  Maryam Navaeian; Samieh Asadian; Hossein Ahmadpour Yazdi; Nematollah Gheibi
Journal:  Mol Biol Rep       Date:  2021-04-17       Impact factor: 2.316

2.  Comparison of 99mTc Pertechnetate Thyroid Uptake Rates by Gamma Probe and Gamma Camera Methods for Differentiating Graves' Disease and Thyroiditis.

Authors:  Meihua Jin; Jonghwa Ahn; Seong-Gil Jo; Jangwon Park; Min Ji Jeon; Won Gu Kim; Tae Yong Kim; Won Bae Kim; Young Kee Shong; Jin-Sook Ryu
Journal:  Nucl Med Mol Imaging       Date:  2022-01-07

3.  Comparison of the therapeutic effects of prednisolone and nonsteroidal anti-inflammatory drugs in patients with subacute thyroiditis.

Authors:  Junko Sato; Toyoyoshi Uchida; Koji Komiya; Hiromasa Goto; Kageumi Takeno; Ruriko Suzuki; Akira Honda; Miwa Himuro; Hirotaka Watada
Journal:  Endocrine       Date:  2016-09-29       Impact factor: 3.633

4.  Role of Diffusion-Weighted Magnetic Resonance (MR) Imaging in Differentiation Between Graves' Disease and Painless Thyroiditis.

Authors:  Ahmed Abdel Khalek Abdel Razek; Sieza Samir Abd Allah; Amr Abd El-Hamid El-Said
Journal:  Pol J Radiol       Date:  2017-09-15

5.  Deep learning for intelligent diagnosis in thyroid scintigraphy.

Authors:  Tingting Qiao; Simin Liu; Zhijun Cui; Xiaqing Yu; Haidong Cai; Huijuan Zhang; Ming Sun; Zhongwei Lv; Dan Li
Journal:  J Int Med Res       Date:  2021-01       Impact factor: 1.671

6.  Cut off value of technetium uptake in the differential diagnosis of Graves, disease and subacute thyroiditis.

Authors:  Demir Fadime
Journal:  Asia Ocean J Nucl Med Biol       Date:  2020
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.